GlassScriptPhysician profile
Daniel A Gutierrez
NPI 1295126464
$6,548.33
in general payments reported to CMS, 2019-2025
23 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $859 · 2023: $1,687 · 2024: $1,665 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,698 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.68 |
| Education | $267.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,309.83 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $1,125.25 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $822.89 | 2021-2025 | |
| Genzyme Corporation | $673.13 | 2021-2025 | |
| Pfizer INC. | $332.50 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $314.42 | 2023-2025 | Sotyktu |
| Incyte Corporation | $247.75 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $234.51 | 2023-2025 | |
| Leo Pharma INC. | $219.62 | 2021-2025 | Adbry, Spevigo |
| Ucb, INC. | $217.57 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $152.42 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $150.02 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $121.09 | 2024-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $117.77 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $97.77 | 2023-2024 | Winlevi, Absorica Ld |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.50 | 2024 | Jublia, Cabtreo, Arazlo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.66 | 2023-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $58.30 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $57.34 | 2024 | Ycanth |
| Krystal Biotech INC | $39.24 | 2024 | Vyjuvek |
| Organon LLC | $38.28 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $28.80 | 2025 | Nuzyra |
| Almirall LLC | $24.67 | 2025 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.